What is amiodarone injection used for?
Pharmaceutical Product Monograph: Amiodarone Hydrochloride Injection (50 mg/mL)
In the pharmaceutical industry, Amiodarone is a potent Class III antiarrhythmic agent. As a pharmacist and manufacturer, I view this molecule as a “Broad-Spectrum Electrophysiological Stabilizer”—it is technically unique because, while classified as Class III, it possesses characteristics of all four Vaughan-Williams classes (I, II, III, and IV).
At your WHO-GMP facility in Mumbai, Amiodarone injection is a critical “Life-Saving” SKU. It is reserved for acute, life-threatening rhythmic disturbances where rapid pharmacological intervention is mandatory.
Therapeutic Profile: Critical Indications
Amiodarone injection is used primarily for the acute treatment and prophylaxis of frequently recurring ventricular arrhythmias.
| Indication | Clinical Context | Technical Rationale |
| Ventricular Fibrillation (VF) | Pulseless Arrest | Used during ACLS (Advanced Cardiovascular Life Support) when VF is unresponsive to defibrillation. |
| Ventricular Tachycardia (VT) | Hemodynamic Instability | Rapidly stabilizes the heart’s electrical rhythm in patients with life-threatening, unstable VT. |
| Atrial Fibrillation (AFib) | Rate/Rhythm Control | Used in acute settings to convert AFib to normal sinus rhythm or to slow a dangerously high heart rate. |
| Post-Surgical Arrhythmias | Cardiac Surgery | Prevents or treats arrhythmias following open-heart surgery. |
Mechanism: Multichannel Blockade
Amiodarone works by lengthening the “reset time” of the heart muscle cells, preventing chaotic electrical signals from taking over:
Potassium Channel Blockade (Class III): Its primary effect is delaying the outward potassium current, which prolongs the Action Potential Duration (APD) and the Effective Refractory Period (ERP) in cardiac tissue.
Sodium Channel Blockade (Class I): It slows the upward stroke of the action potential, reducing conduction velocity.
Beta-Blockade (Class II): It non-competitively inhibits alpha and beta receptors, slowing the heart rate and reducing oxygen demand.
Calcium Channel Blockade (Class IV): It inhibits slow calcium channels, further slowing conduction through the Sinoatrial (SA) and Atrioventricular (AV) nodes.
The Pharmacist’s “Technical Warning”
The “Slow Loading” Rule: As a pharmacist, I must emphasize that except in cardiac arrest, Amiodarone must be infused slowly. Rapid bolus injection can cause severe Hypotension (low blood pressure) and circulatory collapse.
The D5W Mandate: Amiodarone is technically incompatible with Normal Saline (0.9% NaCl) in many concentrations as it can precipitate. It should strictly be diluted in 5% Dextrose (D5W).
In-Line Filter: For B2B hospital clients, remind them that an in-line filter is recommended during infusion to catch any microscopic precipitates.
PVC Interaction: Amiodarone can leach plasticizers from standard PVC tubing. Ideally, non-PVC (DEHP-free) administration sets should be used for prolonged infusions.
Hepatic Toxicity: Acute IV administration has been linked to rapid liver enzyme elevation. Continuous monitoring is required.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Stability & Light” USP: On your digital marketplace, highlight your Amber Ampoule packaging. Amiodarone is light-sensitive; protecting the 150 mg/3 mL solution from UV degradation is a technical hallmark of your WHO-GMP process.
The “ACLS Compliance” Advantage: For international emergency medicine tenders, emphasize that your formulation meets the current 2026 ACLS Guidelines for cardiac arrest protocols.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Amiodarone 50 mg/mL injections to support your registration in international tenders for critical care and cardiology.